Patricia B. Prichep Buys 8,000 Shares of CEL-SCI Co. (NYSE:CVM) Stock

CEL-SCI Co. (NYSE:CVM) SVP Patricia B. Prichep acquired 8,000 shares of CEL-SCI stock in a transaction on Wednesday, May 8th. The shares were bought at an average price of $1.39 per share, for a total transaction of $11,120.00. Following the completion of the purchase, the senior vice president now directly owns 232,326 shares in the company, valued at $322,933.14. The purchase was disclosed in a legal filing with the SEC, which is available through this link.

CEL-SCI Stock Up 8.6 %

CVM traded up $0.12 during midday trading on Thursday, hitting $1.51. 638,187 shares of the company’s stock traded hands, compared to its average volume of 334,349. The company has a market cap of $81.51 million, a PE ratio of -2.12 and a beta of 1.23. The stock’s fifty day simple moving average is $1.80 and its 200-day simple moving average is $2.21. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.26 and a quick ratio of 0.78. CEL-SCI Co. has a one year low of $1.04 and a one year high of $3.23.

CEL-SCI (NYSE:CVM) last issued its quarterly earnings data on Wednesday, February 14th. The company reported ($0.14) earnings per share for the quarter. As a group, equities analysts anticipate that CEL-SCI Co. will post -0.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, StockNews.com cut CEL-SCI from a “hold” rating to a “sell” rating in a research note on Friday, March 15th.

Hedge Funds Weigh In On CEL-SCI

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Chilton Capital Management LLC boosted its holdings in CEL-SCI by 297.4% during the first quarter. Chilton Capital Management LLC now owns 16,302 shares of the company’s stock valued at $31,000 after purchasing an additional 12,200 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of CEL-SCI by 2,011.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 16,198 shares of the company’s stock worth $44,000 after purchasing an additional 15,431 shares in the last quarter. Forthright Family Wealth Advisory LLC bought a new position in CEL-SCI during the 4th quarter valued at about $45,000. Sheets Smith Wealth Management acquired a new position in CEL-SCI in the fourth quarter valued at about $54,000. Finally, Black Diamond Financial LLC increased its holdings in shares of CEL-SCI by 20.5% during the third quarter. Black Diamond Financial LLC now owns 53,000 shares of the company’s stock worth $66,000 after buying an additional 9,000 shares in the last quarter. 12.08% of the stock is currently owned by institutional investors.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.